 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...4567891011121314...1718» |
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial completion date, Trial primary completion date, Combination therapy: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Nov 10, 2019
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2020 --> Jan 2020 | Trial primary completion date: Jul 2019 --> Jan 2020
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Window-2: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 10, 2019
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2020 --> Jan 2020 | Trial primary completion date: Jul 2019 --> Jan 2020 Trial completion date: May 2023 --> May 2021
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - Nov 4, 2019
P3, N=3698, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: May 2023 --> May 2021 Not yet recruiting --> Recruiting
- | Vanflyta (quizartinib) / Daiichi Sankyo
Enrollment open, Trial completion date, Trial primary completion date: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 2, 2019
P2, N=86, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Feb 2022 | Trial primary completion date: Jan 2023 --> Feb 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 1, 2019
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Feb 2022 | Trial primary completion date: Jan 2023 --> Feb 2022 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Calquence (acalabrutinib) / AstraZeneca
Enrollment open: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 20, 2019
P2, N=369, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial primary completion date: FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 17, 2019
P2, N=57, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2019 --> Jul 2020
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 9, 2019
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2019 --> Jul 2020 Trial completion date: Jul 2019 --> Oct 2020 | Trial primary completion date: Jul 2019 --> Oct 2020
- | Vanflyta (quizartinib) / Daiichi Sankyo
Trial initiation date, Trial primary completion date: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 8, 2019
P2, N=86, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2019 --> Oct 2020 | Trial primary completion date: Jul 2019 --> Oct 2020 Initiation date: Aug 2019 --> Jan 2020 | Trial primary completion date: Feb 2022 --> Jan 2023
- | Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 4, 2019
P3, N=302, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2019 --> Jan 2020 | Trial primary completion date: Feb 2022 --> Jan 2023 Suspended --> Recruiting
- | Jakafi (ruxolitinib) / Incyte
Enrollment open: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 4, 2019
P2, N=12, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Active, not recruiting --> Recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed: s16-00955: Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 4, 2019
P1/2, N=38, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting Completed --> Active, not recruiting
- | Trial completion date, Trial primary completion date: CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma (clinicaltrials.gov) - Oct 3, 2019
P1/2, N=36, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting Trial completion date: Jan 2020 --> Mar 2021 | Trial primary completion date: Jan 2020 --> Mar 2021
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Calquence (acalabrutinib) / AstraZeneca
New P2 trial: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 3, 2019
P2, N=369, Not yet recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 3, 2019
P3, N=598, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2020 --> Mar 2021 | Trial primary completion date: Jan 2020 --> Mar 2021 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial completion date, Trial primary completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Sep 23, 2019
P2, N=136, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- | arsenic trioxide / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia (clinicaltrials.gov) - Sep 16, 2019
P3, N=108, Completed, Sponsor: Children's Oncology Group
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Active, not recruiting --> Completed
- | leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial completion: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 10, 2019
P3, N=3154, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | 90Y-BC8-DOTA / Fred Hutchinson Cancer Center
Trial completion date: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (clinicaltrials.gov) - Sep 10, 2019
P1/2, N=20, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Jul 2020
- | Combotox (Imtox19/Imtox22) / Montefiore Medical Center, National Cancer Institute, Abiogen
Trial termination, Combination therapy: Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2019
P1, N=18, Terminated, Sponsor: Albert Einstein College of Medicine
Trial completion date: Jul 2021 --> Jul 2020 Recruiting --> Terminated
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2019
P2, N=53, Suspended, Sponsor: Children's Oncology Group
Recruiting --> Terminated Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (clinicaltrials.gov) - Aug 30, 2019
P1/2, N=18, Recruiting, Sponsor: AIDS Malignancy Consortium
Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Trial completion date: Jun 2034 --> Jun 2036 | Trial primary completion date: Sep 2019 --> Sep 2021
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Aug 15, 2019
P2, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Jun 2034 --> Jun 2036 | Trial primary completion date: Sep 2019 --> Sep 2021 Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2020
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Enrollment closed: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Aug 14, 2019
P3, N=5956, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2020 Suspended --> Active, not recruiting
- | Vanflyta (quizartinib) / Daiichi Sankyo
New P2 trial: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 7, 2019
P2, N=86, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Venclexta (venetoclax) / Roche, AbbVie
Enrollment change, Trial completion date, Trial primary completion date: NCI-2014-01103: Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Aug 5, 2019
P2, N=408, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting N=308 --> 408 | Trial completion date: May 2019 --> May 2022 | Trial primary completion date: May 2019 --> May 2021
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, milademetan (RAIN-32) / Rain Oncology
Enrollment change, Trial completion date, Combination therapy: Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 15, 2019
P1/2, N=32, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=308 --> 408 | Trial completion date: May 2019 --> May 2022 | Trial primary completion date: May 2019 --> May 2021 N=52 --> 32 | Trial completion date: May 2020 --> May 2021
- | tosedostat (CHR-2797) / SOBI
Trial completion, Trial completion date, Trial primary completion date: Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 10, 2019
P1/2, N=96, Completed, Sponsor: M.D. Anderson Cancer Center
N=52 --> 32 | Trial completion date: May 2020 --> May 2021 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Nov 2019 --> Jul 2019
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 8, 2019
P1/2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Nov 2019 --> Jul 2019 Trial completion date: Dec 2023 --> Dec 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 7, 2019
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting
- | thioguanine / Generic mfg.
Enrollment open: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Jul 5, 2019
P2, N=136, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | Vesanoid (tretinoin) / Roche
Enrollment closed: Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov) - Jun 28, 2019
P3, N=158, Active, not recruiting, Sponsor: Children's Oncology Group
Suspended --> Recruiting Recruiting --> Active, not recruiting
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial suspension: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 28, 2019
P2, N=53, Suspended, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Suspended
- | Jakafi (ruxolitinib) / Incyte
Enrollment closed, Enrollment change: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 20, 2019
P2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=92 --> 12
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Enrollment change: Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 17, 2019
P1/2, N=44, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=92 --> 12 N=22 --> 44
- | peposertib (M3814) / EMD Serono
New P1 trial, Combination therapy: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 12, 2019
P1, N=48, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date: NCI-2018-01318: Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 6, 2019
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=22 --> 44 Trial completion date: Jan 2020 --> Jan 2021
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial completion date: Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 4, 2019
P1/2, N=22, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2020 --> Jan 2021 Trial completion date: May 2020 --> May 2021
- | dasatinib / Generic mfg.
Trial completion date: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Jun 3, 2019
P2, N=107, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2020 --> May 2021 Trial completion date: Aug 2020 --> Aug 2021
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Phase classification: Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms (clinicaltrials.gov) - Jun 3, 2019
P2, N=30, Recruiting, Sponsor: University of Washington
Trial completion date: Aug 2020 --> Aug 2021 Phase classification: P=N/A --> P2
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial completion date: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 30, 2019
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P=N/A --> P2 Trial completion date: Oct 2021 --> Oct 2020
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - May 30, 2019
P2, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Oct 2021 --> Oct 2020 Trial completion date: May 2019 --> Aug 2019 | Trial primary completion date: May 2019 --> Aug 2019
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - May 29, 2019
P3, N=1400, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2019 --> Aug 2019 | Trial primary completion date: May 2019 --> Aug 2019 Suspended --> Active, not recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Window-2: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - May 24, 2019
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting Trial completion date: Apr 2021 --> May 2023
- | Qinprezo (vosaroxin) / Denovo
Enrollment closed, Combination therapy, Tumor mutational burden: VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - May 24, 2019
P2, N=61, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Apr 2021 --> May 2023 Suspended --> Active, not recruiting
- | Vanflyta (quizartinib) / Daiichi Sankyo
Enrollment change: NCI-2018-01813: Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - May 23, 2019
P1/2, N=200, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting N=78 --> 200
- | Ninlaro (ixazomib) / Takeda
Enrollment closed, Enrollment change: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma (clinicaltrials.gov) - May 23, 2019
P1, N=11, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=78 --> 200 Recruiting --> Active, not recruiting | N=24 --> 11
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P3 trial: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - May 21, 2019
P3, N=3698, Not yet recruiting, Sponsor: Children's Oncology Group
- | Jakafi (ruxolitinib) / Incyte
Trial completion date: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 20, 2019
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=24 --> 11 Trial completion date: Jul 2023 --> Jul 2024
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 16, 2019
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2023 --> Jul 2024 Trial completion date: Nov 2021 --> Nov 2020